Gilead Sciences, Inc. announced the detailed results from the Phase 3 IDEAL study, which demonstrated that the majority of participants living with PBC and treated with Livdelzi (seladelpar)… read more.
Johnson & Johnson announced results from three clinical analyses being presented during the Transcatheter Cardiovascular Therapeutics annual scientific symposium (TCT 2026) that report positive survival and patient outcomes… read more.
Ionis Pharmaceuticals, Inc. announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending the indication extension for… read more.
HUTCHMED Limited announces positive results from the SANOVO Phase III trial in China. Orpathys (savolitinib) plus Tagrisso (osimertinib) demonstrated a statistically significant and highly clinically meaningful improvement in… read more.
Johnson & Johnson announced that the FDA granted accelerated approval for RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) (subcutaneous injection, 160 mg/2,000 units per mL) as a single agent for… read more.
Astellas Pharma Inc. announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has accepted a New Drug Application (NDA) for Veoza… read more.
On 30 October 2026, the MHRA granted Dojolvi (triheptanoin), an oral liquid, conditional marketing authorisation to treat adult and paediatric patients with long-chain fatty acid oxidation disorders (LC-FAOD)…. read more.
Ascendis Pharma announced new data demonstrating early, sustained, and clinically meaningful improvements in kidney function in adults with hypoparathyroidism treated with TransCon PTH (palopegteriparatide) for up to 5… read more.
Syndax Pharmaceuticals will present 19 abstracts at the 68th ASH Annual Meeting (12–15 December 2026). Fourteen cover revumenib (Revuforj), including seven oral presentations, and five cover axatilimab (Niktimvo)…. read more.
Rigel Pharmaceuticals will present updated Phase 1b data for R289 at the 68th ASH Annual Meeting, in an oral session on 12 December 2026. R289 is the company’s… read more.
Merck, known as MSD outside of the United States and Canada, announced the initiation of ENHANCE-3 (NCT07874815), a Phase 3 randomized clinical trial evaluating OHTUVAYRE (ensifentrine) for the… read more.
Lyell Immunopharma will present updated data for rondecabtagene autoleucel (ronde-cel), its investigational dual-targeting CD19/CD20 CAR T-cell therapy, in relapsed or refractory large B-cell lymphoma (LBCL). The data will… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
